TY - JOUR
AU - Turco, Fabio
AU - Armstrong, Andrew
AU - Attard, Gerhardt
AU - Beer, Tomasz M
AU - Beltran, Himisha
AU - Bjartell, Anders
AU - Bossi, Alberto
AU - Briganti, Alberto
AU - Bristow, Rob G
AU - Bulbul, Muhammad
AU - Caffo, Orazio
AU - Chi, Kim N
AU - Clarke, Caroline S
AU - Clarke, Noel
AU - Davis, Ian D
AU - de Bono, Johann
AU - Duran, Ignacio
AU - Eeles, Ros
AU - Efstathiou, Eleni
AU - Efstathiou, Jason
AU - Evans, Christopher
AU - Fanti, Stefano
AU - Feng, Felix Y
AU - Fizazi, Karim
AU - Frydenberg, Mark
AU - George, Dan
AU - Gleave, Martin
AU - Halabi, Susan
AU - Heinrich, Daniel
AU - Higano, Celestia
AU - Hofman, Michael S
AU - Hussain, Maha
AU - James, Nicholas
AU - Jones, Rob
AU - Kanesvaran, Ravindran
AU - Khauli, Raja B
AU - Klotz, Laurence
AU - Leibowitz, Raya
AU - Logothetis, Christopher
AU - Maluf, Fernando
AU - Millman, Robin
AU - Morgans, Alicia K
AU - Morris, Michael J
AU - Mottet, Nicolas
AU - Mrabti, Hind
AU - Murphy, Declan G
AU - Murthy, Vedang
AU - Oh, William K
AU - Ekeke, Onyeanunam N
AU - Ost, Piet
AU - O'Sullivan, Joe M
AU - Padhani, Anwar R
AU - Parker, Christopher
AU - Poon, Darren M C
AU - Pritchard, Colin C
AU - Rabah, Danny M
AU - Rathkopf, Dana
AU - Reiter, Robert E
AU - Rubin, Mark
AU - Ryan, Charles J
AU - Saad, Fred
AU - Sade, Juan Pablo
AU - Sartor, Oliver
AU - Scher, Howard I
AU - Shore, Neal
AU - Skoneczna, Iwona
AU - Small, Eric
AU - Smith, Matthew
AU - Soule, Howard
AU - Spratt, Daniel E
AU - Sternberg, Cora N
AU - Suzuki, Hiroyoshi
AU - Sweeney, Christopher
AU - Sydes, Matthew R
AU - Taplin, Mary-Ellen
AU - Tilki, Derya
AU - Tombal, Bertrand
AU - Türkeri, Levent
AU - Uemura, Hiroji
AU - Uemura, Hirotsugu
AU - van Oort, Inge
AU - Yamoah, Kosj
AU - Ye, Dingwei
AU - Zapatero, Almudena
AU - Gillessen, Silke
AU - Omlin, Aurelius
PY - 2022
DA - February
TI - What experts think about prostate cancer management during the COVID-19 pandemic: report from the Advanced Prostate Cancer Consensus Conference 2021
JO -  European Urology
DO - http://dx.doi.org/10.1016/j.eururo.2022.02.010
AB - Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients.
PB - Elsevier
UR - http://eprints.gla.ac.uk/269542/
KW - Coronavirus (COVID-19)
KW - Digital health and technology
KW - Immunisation and screening
ER